NOV (NOV)
(Delayed Data from NYSE)
$11.96 USD
-0.27 (-2.21%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $11.96 0.00 (0.00%) 7:24 PM ET
5-Strong Sell of 5 5
A Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NOV 11.96 -0.27(-2.21%)
Will NOV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NOV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NOV
NOV Q2 Earnings Miss, Revenues Beat Estimates, Both Decrease Y/Y
Here's What Key Metrics Tell Us About Nov Inc. (NOV) Q2 Earnings
NOV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nov Inc. (NOV) Q2 Earnings Miss Estimates
Oil States International (OIS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Factors You Need to Know Ahead of NOV's Q2 Earnings Release
Other News for NOV
Novo Nordisk downgraded to Neutral from Buy at UBS
RBC Capital Maintains Rating on NOV, Lowers Price Target | NOV Stock News
NOV Stock Rating Maintained, Price Target Lowered by Evercore ISI Group | NOV Stock News
JP Morgan Downgrades NOV, Lowers Price Target to $15.00 | NOV Stock News
NOV Price Target Reduced by Susquehanna Amid Diverse Global Opportunities